258 related articles for article (PubMed ID: 7994271)
21. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
22. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
23. Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen.
Kalaycioglu ME; Bolwell BJ
Bone Marrow Transplant; 1994 Jul; 14(1):113-5. PubMed ID: 7951097
[TBL] [Abstract][Full Text] [Related]
24. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
Bertz H; Potthoff K; Mertelsmann R; Finke J
Bone Marrow Transplant; 1997 Jun; 19(12):1169-73. PubMed ID: 9208109
[TBL] [Abstract][Full Text] [Related]
25. Bone marrow transplantation following busulfan and cyclophosphamide for acute myelogenous leukemia.
Crilley P; Topolsky D; Bulova S; Bigler R; Brodsky I
Bone Marrow Transplant; 1990 Mar; 5(3):187-91. PubMed ID: 2331539
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
Matsuyama T; Kojima S; Kato K
Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
[TBL] [Abstract][Full Text] [Related]
28. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
29. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC).
Ratanatharathorn V; Karanes C; Lum LG; Uberti J; Dan ME; de Planque MM; Schultz KR; Cronin S; Leisz MC; Mohamed A
Bone Marrow Transplant; 1992 Jan; 9(1):49-55. PubMed ID: 1543949
[TBL] [Abstract][Full Text] [Related]
31. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
von Bueltzingsloewen A; Esperou-Bourdeau H; Souillet G; Demeocq F; Mechinaud-Lacroix F; Michel G; Sadoun A; Bernaudin F; Cornu G; Donadieu J
Bone Marrow Transplant; 1995 Oct; 16(4):521-7. PubMed ID: 8528167
[TBL] [Abstract][Full Text] [Related]
33. Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.
Fujimaki K; Taguchi J; Fujita H; Hattori M; Yamazaki E; Takahashi N; Fujisawa S; Kanamori H; Maruta A; Ishigatsubo Y
Bone Marrow Transplant; 2004 Apr; 33(8):789-92. PubMed ID: 15064685
[TBL] [Abstract][Full Text] [Related]
34. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
[TBL] [Abstract][Full Text] [Related]
35. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
[TBL] [Abstract][Full Text] [Related]
36. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
Lu C; Braine HG; Kaizer H; Saral R; Tutschka PJ; Santos GW
Cancer Treat Rep; 1984 May; 68(5):711-7. PubMed ID: 6373004
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
[TBL] [Abstract][Full Text] [Related]
38. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
[TBL] [Abstract][Full Text] [Related]
40. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma.
Przepiorka D; Nath R; Ippoliti C; Mehra R; Hagemeister F; Diener K; Dimopoulos M; Giralt S; Khouri I; Samuels B
Leuk Lymphoma; 1995 May; 17(5-6):427-33. PubMed ID: 7549833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
